heartbeam.com (BEAT): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Brandmark of HeartBeam Corp (BEAT)

HeartBeam, Inc. (BEAT) is relying on internal verification of its systems without merger deals, planning to integrate AI algorithms into third-party care services. The business faces pressure from mass-market gadgets that are displacing niche sensors. This chart of the company's price action with the 0.00 indicator underscores the brand's status as a creator of portable ECG devices for precise remote cardiac health monitoring.

BEAT (HeartBeam Inc) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/11/2026

BEAT (heartbeam.com): analytical breakdowns and indicator data

- current price and projected stock value:
Stock Price HeartBeam Corp|BEAT - Analyst Consensus Forecast
- stock exchange capitalization data:
Market Value HeartBeam Corporation|BEAT - Value Adjusted for Debt and Cash
- book value of equity indicators:
Accounting Value per Share HeartBeam|BEAT - Total Net Assets|Market Capitalization to Book Value Ratio heartbeam.com|BEAT - Aggregate Company Assets
- debt and solvency information:
Total Debt to Capital HeartBeam, Inc.|BEAT - Long-Term Liabilities to Capital|Short-Term Debt to Capital HeartBeam|BEAT - Company Aggregate Debts|Debt to Book Capitalization Ratio HeartBeam Corporation|BEAT - Company Long-Term Liabilities|Company Current Liabilities HeartBeam|Quick Ratio heartbeam.com
- net income and valuation multiples indicators:
BEAT - Net Financial Result|Expected Profit HeartBeam, Inc.|BEAT - Price to Earnings Multiple|Forward P/E Multiple HeartBeam, Inc.|BEAT - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio HeartBeam Corporation|BEAT - Operating income before deduction of amortization|Net earnings per share (EPS TTM) HeartBeam|BEAT - Earnings per share for the last twelve months|Quarterly EPS earnings growth heartbeam.com|BEAT - Earnings per share growth rate in current year|Earnings growth forecast for next year HeartBeam, Inc.
Fundamental company analysis:BEAT (HeartBeam Corp)
Product sample of heartbeam.com

Protecting the technological advantage of HeartBeam, Inc. (BEAT) through complex FDA certifications and a patent moat requires significant capital expenditures, making the debt structure critically important. By analyzing changes in the EV/EBITDA ratio, an investor assesses the total enterprise value relative to operating profit, where a decline in the metric signals either undervalued assets or an increasing debt load.

Competitors of HeartBeam, Inc. (BEAT)

EV/EBITDA Multiple REGN (Regeneron Inc.)|EV/EBITDA Multiple iRhythm Corp IRTC|LNTH - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation MLYS (mineralystx.com)|HTFL (HeartFlow Corp) - Enterprise Value to EBITDA Ratio|KMTS: Enterprise Value to Operating Income Before Depreciation Ratio|ESPR (Esperion Therapeutics Inc) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization AMRN|EV/EBITDA Multiple AVR|TNYA - Company Value to EBITDA|EV/EBITDA Multiple CVRX (CVRx)|EV/EBITDA Multiple Milestone Pharmaceuticals, Inc. MIST|CRDL - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Tenax Therapeutics Inc (TENX) - Enterprise Value to EBITDA Ratio|ADGM (Adagio Medical Holdings) - Enterprise Value to EBITDA Ratio|biocardia.com - Business Value to Operating Income Before Depreciation|VTAK (Catheter Precision, Inc.) - EV/EBITDA Multiple|ARCA Bio (ABIO) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acasti Pharma (ACST)|Aerovate Therapeutics, Inc - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple VERV (Verve Therapeutics, Inc.)|WINT - Enterprise Value to EBITDA Ratio